Alnylam Pharmaceuticals, Inc. has announced the promotion of Pushkal Garg, M.D., to the position of Executive Vice President and Chief Research and Development Officer. This move comes as the company is entering a new phase of growth, building on the launch of AMVUTTRA® in transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The combined research and development organization is expected to accelerate pipeline progress by fostering earlier collaboration, faster decision-making, and more agile responses to scientific opportunity and patient need.
In recent years, Alnylam has made significant progress across all facets of its innovation engine, achieving numerous drug approvals and positive Phase 3 readouts. The company has rapidly increased the size of its clinical pipeline as its science has advanced.
Dr. Garg, who joined Alnylam in 2014, expressed his excitement about the future of RNAi therapeutics and the potential to improve human health. His vision is to deliver RNAi therapeutics to every major tissue in the body, addressing many additional diseases that lack effective treatments.
Key facts and figures about Alnylam Pharmaceuticals, Inc. and RNAi therapeutics: RNA interference (RNAi) is a natural cellular process of gene silencing and represents a rapidly advancing frontier in biology and drug development. Alnylam's RNAi therapeutic platform utilizes small interfering RNA (siRNA) to silence messenger RNA (mRNA), thus preventing the production of disease-causing or disease pathway proteins. Since its founding in 2002, Alnylam has led the translation of RNAi into a new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet needs. The company has a deep pipeline of investigational medicines, including multiple product candidates in late-stage development, reflecting its commitment to delivering transformative medicines in both rare and common diseases.
Alnylam Pharmaceuticals, Inc. is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases, aiming to benefit patients around the world through sustainable innovation and exceptional financial performance. The market has reacted to these announcements by moving the company's shares 1.17% to a price of $312.32. If you want to know more, read the company's complete 8-K report here.
